Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Rang in Aktien #33638
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Aktienkurs
$0.03702159
Zuletzt synchronisiert: 2024-01-29
Marktkapitalisierung
$7.21M
Veränderung (1 Tag)
-3.08%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel Antisense Therapeutics Limited (ANP)

Kategorie

Aktien-Split-Historie für Antisense Therapeutics Limited (ANP)
Die Aktie Antisense Therapeutics Limited (Symbol: ANP) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 17, 2026 statt.
Eine ANP-Aktie, die vor dem Aug 17, 2026 gekauft wurde, entspricht heute 0 ANP-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber